Low Phosphate Diets in Patients With Early Stages of Chronic Kidney Disease

This study has been completed.

Study NCT00438932 Information provided by Massachusetts General Hospital

First Received on February 20, 2007. Last Updated on September 23, 2011 History of Changes

Results First Received: July 25, 2011

Study Type:	Interventional
Study Design:	Allocation: Randomized; Endpoint Classification: Efficacy Study; Intervention Model: Factorial Assignment; Masking: Single Blind (Subject); Primary Purpose: Prevention
Condition:	Chronic Kidney Disease
Interventions:	Drug: Lanthanum Carbonate Dietary Supplement: Low Phosphorus Diet Dietary Supplement: Unrestricted Phosphorus Diet Drug: Placebo

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
16 patients completed the full study. Patients were recruited from renal clinics.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
There was no wash-out, run in or transition.

Reporting Groups

	Description
Lanthanum Carbonate & Low Phosphorous Diet	Lanthanum carbonate 1000mg 3x/day and low phosphorus diet of 800 mg of phosphorus per day.
Lanthanum Carbonate & Unrestricted Phosphorous Diet	Lanthanum carbonate 1000mg 3x/day and unrestricted diet containing 1550 mg of phosphorus per day - 800 mg of which is dietary and 750mg of Neutraphos (3 packets/day); each packet is 250mg.
Placebo & Low Phosphorous Diet	Placebo and low phosphorus diet consisting of 800 mg of phosphorus per day.
Placebo & Unrestricted Phosphorous Diet	Placebo and unrestricted diet containing 1550 mg of phosphorus per day - 800 mg of which is dietary and 750mg of Neutraphos (3 packets/day); each packet is 250mg.

Participant Flow: Overall Study

	Lanthanum Carbonate & Low Phosphorous Diet	Lanthanum Carbonate & Unrestricted Phosphorous Diet	Placebo & Low Phosphorous Diet	Placebo & Unrestricted Phosphorous Diet
STARTED	4	4	4	4
COMPLETED	4	4	4	4
NOT COMPLETED	0	0	0	0

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
Lanthanum Carbonate & Low Phosphorous Diet	Lanthanum carbonate 1000mg 3x/day and low phosphorus diet of 800 mg of phosphorus per day.
Lanthanum Carbonate & Unrestricted Phosphorous Diet	Lanthanum carbonate 1000mg 3x/day and unrestricted diet containing 1550 mg of phosphorus per day - 800 mg of which is dietary and 750mg of Neutraphos (3 packets/day); each packet is 250mg.
Placebo & Low Phosphorous Diet	Placebo and low phosphorus diet consisting of 800 mg of phosphorus per day.
Placebo & Unrestricted Phosphorous Diet	Placebo and unrestricted diet containing 1550 mg of phosphorus per day - 800 mg of which is dietary and 750mg of Neutraphos (3 packets/day); each packet is 250mg.

Baseline Measures

	Lanthanum Carbonate & Low Phosphorous Diet	Lanthanum Carbonate & Unrestricted Phosphorous Diet	Placebo & Low Phosphorous Diet	Placebo & Unrestricted Phosphorous Diet	Total
Number of Participants [units: participants]	4	4	4	4	16
Age [units: participants]
<=18 years	0	0	0	0	0
Between 18 and 65 years	3	3	2	2	10
>=65 years	1	1	2	2	6
Age [units: years] Mean ± Standard Deviation	63 ± 11	62 ± 13	56 ± 21	68 ± 17	62 ± 15
Gender [units: participants]
Female	1	0	0	0	1
Male	3	4	4	4	15
Region of Enrollment [units: participants]
United States	4	4	4	4	16
Fibroblast Growth Factor 23 (FGF-23) ^[1] [units: Ru/ml] Mean ± Standard Deviation	164.3 ± 110.9	263.1 ± 167.9	178.8 ± 97.6	121.8 ± 60.0	182.0 ± 116.3
24-hr urine phosphate ^[2] [units: mg] Mean ± Standard Deviation	659.0 ± 269.8	761.8 ± 77.4	745.4 ± 287.0	934.6 ± 545.5	775.2 ± 320.0

[1]	Plasma FGF-23 at the baseline visit was measured using C-terminal FGF23 assay.
[2]	measured from 24 hour urine collections; 2 separate collections were obtained; values are means of the two collections; pre-intervention

Outcome Measures

Show All Outcome Measures

1. Primary:

Fibroblast Growth Factor 23 (FGF-23) [ Time Frame: 2 weeks ]

Show Outcome Measure 1

2. Secondary:

24-hour Urinary Phosphate [ Time Frame: 2 weeks ]

Show Outcome Measure 2

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
In addition to limited power, the small sample size led to imbalances in baseline laboratory tests, which added further variability to the analyses. .

Results Point of Contact:

Name/Title: Tamara Isakova, MD, MMSc
Organization: University of Miami Miller School of Medicine
phone: 305-243-4374
e-mail: tisakova@med.miami.edu

Publications of Results:

Isakova T, Gutiérrez OM, Smith K, Epstein M, Keating LK, Jüppner H, Wolf M. Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant. 2011 Feb;26(2):584-91. Epub 2010 Jul 14.

Responsible Party:	Myles S. Wolf, Massachusetts General Hospital
ClinicalTrials.gov Identifier:	NCT00438932 History of Changes
Other Study ID Numbers:	2005P000486
Study First Received:	February 20, 2007
Results First Received:	July 25, 2011
Last Updated:	September 23, 2011
Health Authority:	United States: Food and Drug Administration